Letrozol Orifarm

Letrozole, the active ingredient in Letrozol Orifarm, is an aromatase inhibitor presented as a tablet for oral use. It reduces estrogen production and is used in the treatment of postmenopausal estrogen receptor‑positive breast cancer. GNH USA supplies Letrozol Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole acts on the estrogen‑dependent pathway of breast cancer, providing endocrine therapy for hormone‑responsive disease. - Postmenopausal estrogen receptor‑positive breast cancer: lowers recurrence risk and slows disease progression. - Adjuvant treatment of hormone‑responsive breast cancer: improves disease‑free survival after surgery. - Metastatic breast cancer in postmenopausal women: delays tumor growth and extends survival.

Letrozole may cause a range of adverse reactions, from mild to severe. Patients should be monitored for both common and serious events.

Common Side Effects: - Hot flashes: transient episodes of intense warmth. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Pulmonary embolism: sudden shortness of breath. - Bone fracture: increased risk due to reduced bone density. - Allergic reaction: rash, swelling, or anaphylaxis. - Elevated cholesterol: hyperlipidaemia. - Cardiac arrhythmia: QT prolongation.

Before initiating Letrozol Orifarm, clinicians should assess patient-specific risk factors and monitor therapy closely. - Bone health monitoring: perform baseline and periodic DEXA scans. - Liver function assessment: check transaminases prior to and during treatment. - Cardiovascular risk evaluation: monitor blood pressure and lipid profile. - Pregnancy avoidance: contraindicated in pregnancy (Category X). - Elderly caution: start at lowest effective dose and monitor for toxicity. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Letrozole can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels. - Estrogen‑containing hormonal therapy: antagonizes letrozole's anti‑estrogen effect. - Live hormonal vaccines: potential reduced vaccine efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring closer coagulation monitoring. - Cholesterol‑lowering agents (statins): possible additive effect on liver enzymes. - Antidepressants (SSRIs): may influence hormone metabolism. - Antifungal azoles (ketoconazole): can increase letrozole exposure. - Herbal supplements (St. John’s wort): may induce metabolism and lower efficacy.